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First outbreak described in
the U.S. in 1843
More than 21,000 paralytic















Minimal heterotypic immunity between serotypes
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Most infectious: 7-10 days before 
onset 
Virus present in stool            
3-6 weeks
Poliomyelitis—United States, 1950-2011

































1955 - Inactivated vaccine
1963 - Trivalent OPV






Highly effective in producing immunity to poliovirus
≥90% of recipients immune after 2 doses
≥99% of recipients immune after 3 doses
Duration of immunity not known with certainty

Childhood Polio Vaccination Schedule
IPV Dose  Routinely Recommended at 
Minimum 
Interval 
1 2 months of age ----------
2 4 months of age 4 weeks 
3 6- 18 months of age 4 weeks 





In the first 6 months of life, minimum age and minimum
intervals are only recommended if the person is at risk of
imminent exposure to circulating poliovirus
If 4 or more doses are administered before age 4 years, an
additional dose should be administered at age 4 through 6
years and at least 6 months after the previous dose
A fourth dose is not necessary if the third dose was
administered at age 4 years or older and at least 6 months
after the previous dose
www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf
Schedules that Include 




Only IPV is available in the United States
If both OPV and IPV were administered as part of a series, 
the series should be completed with IPV.  Any combination 
of 4 doses of OPV and IPV by 4 to 6 years of age constitutes a 
complete series
If only OPV doses were administered, and all doses were 
given prior to 4 years of age, one dose of IPV should be given 
at 4 years or older, at least 4 weeks after the last OPV dose







Single component vaccine - IPV (IPOL)











IPV doses 1 through 4
Children 6 weeks through 4 years of age
Use DTaP-IPV diluent to reconstitute the Hib component








FDA-approved for:  
IPV doses 1 through 3 
Children 6 weeks through 6 years of age 








IPV dose 4 
Children 4 through 6 years of age 
Quadracel
IPV dose 4 or 5
4 through 6 years of age 
VA error: Do NOT use to reconstitute the Hib component of 
Pentacel vaccine 
Polio Vaccination of Adolescents and Adults


Routine vaccination of U.S. residents 18 years of age or older 
is not necessary or recommended
May consider vaccination of travelers to polio-endemic 
countries and selected lab workers 





Use standard IPV schedule if possible 
0, 1-2 months, 6-12 months intervals
May separate first and second doses by 4 weeks if 
accelerated schedule needed 
The minimum interval between the second and third doses 
is 6 months








Administer 1 dose of IPV to those at risk
Incomplete series
Administer remaining doses in series based on immunization history
No need to restart a valid documented series 
Valid = minimum intervals met 
Contraindications and Precautions 
 Severe allergic reaction to a vaccine component or following 
a prior dose of vaccine




Local reactions 2.8% (pain, redness, swelling)
Severe reactions rare
Polio Eradication 
 Last case in the United States in 1979
 Western Hemisphere certified polio-free in 1994
 Last isolate of WPV2 was in India in October 1999
 Global eradication goal 
Global Polio Efforts
 The number of worldwide reported cases has decreased from an 
estimated 350,000 in 1988 to 19 as of June 29, 2016
 Afghanistan – 6 cases of WPV1
 Pakistan – 13 cases of WPV1
 Nigeria – Polio-free
http://www.polioeradication.org
http://www.who.int/immunization/diseases/poliomyelitis/endgame_objective2/oral_polio_vaccine/en/
Haemophilus influenzae Type b and Hib Vaccine








Severe bacterial infection, particularly among infants
Aerobic gram-negative bacteria
Polysaccharide capsule 
6 different serotypes (a-f) of polysaccharide capsule
95% of invasive disease caused by type b (prevaccine era)




Formerly the leading cause of bacterial meningitis among 
children younger than 5 years of age
Approximately 1 in 200 children developed invasive Hib
disease
Almost all infections among children younger than 5 years






















Reservoir Human asymptomatic carriers
Transmission Respiratory droplets presumed
Temporal pattern Peaks in Sept-Dec and March-May
Communicability
Generally limited but higher in 
some circumstances (e.g., 
household, child care)
Estimated Annual Incidence (per 100,000) of 
Invasive Haemophilus influenzae Type b (Hib) Disease in 
Children Aged <5 Years — United States, 1980–2012
MMWR 2014;63(RR1):1-14.
Haemophilus influenzae, Invasive Disease
Incidence of reported cases (per 100,000), by serotype 
among children aged <5 years — United States, 2000–2013
MMWR 2015;62(53):1-119.
0.27 per 100,000 
Healthy People 2020 Goal








Not effective in children younger than 18 months of age 
Efficacy in older children varied 
Age-dependent immune response 
Not consistently immunogenic in children 2 years of age and 
younger 
No booster response 







Immune response with booster doses
Same polysaccharide capsule linked to different carrier 
proteins
3 monovalent conjugate vaccines





















Recommended interval 8 weeks for primary series
Minimum interval 4 weeks for primary series
Minimum age 6 weeks
Booster dose at 12-15 months
Hib Vaccine Routine  Schedule
Vaccine 2 months 4 months 6 months
12-18 
months
PRP-T X X X X
PRP-OMP X X NA X




Children starting late may not need entire 3 or 4 dose series 
Number of doses child requires depends on current age
See detailed schedule p. 128 of Pink Book, and 2016 catch-up 
schedule
Hib Vaccine








Generally not recommended for persons older than 59 months 
of age
High-risk older children and adolescents may be vaccinated if 




Receipt of chemotherapy or radiation therapy 
Special populations
Guidance for Hib Vaccination in High-risk Groups
High-risk group Hib vaccine guidance
Elective splenectomy If unimmunized: 
1 dose, prior to procedure
Asplenic patient If unimmunized: 1 dose
HIV-infected children If unimmunized: 1 dose
HIV-infected adults Hib vaccination not recommended
Hematopoietic cell transplant 3 doses (at least 4 weeks apart) 









Children aged <24 months with invasive Hib disease
Administer complete series as recommended for child’s age
Vaccinate during the convalescent phase of the illness
American Indian/ Alaska Natives
PRP-OMP vaccines specifically recommended for primary series doses
Hib disease peaks earlier in infancy













Approved for all doses of primary schedule and booster dose
Can be used for previously unvaccinated children per the 
catch-up schedule





Approved for all doses of primary schedule and booster dose






Approved for all doses of primary schedule and booster dose
Remember primary series for PRP-OMP vaccines is 2 doses












Contains DTaP, Hib (PRP-T), and IPV
Approved for doses 1 through 4 among children 6 weeks 
through 4 years of age
Do NOT use for children 5 years or older
Package contains lyophilized Hib (ActHIB) that is 







Contains Hib (PRP-T) and Neisseria meningitidis serogroups C 
and Y
Approved for 4 doses between 6 weeks and 18 months of 
age
Only recommended for routine meningococcal vaccination 
of infants who are at increased risk for meningococcal 
disease
Persistent complement pathway deficiencies 






All monovalent conjugate Hib vaccines are interchangeable 
for primary series and booster dose
3-dose primary series (4 doses total) if more than one brand 
of vaccine used at 2 or 4 months of age
Whenever feasible use same combination vaccine for 
subsequent doses
If vaccine used for earlier doses is not known or not 






Hepatitis B-Hib (PRP-OMP) combination
Removed from existing contracts and pricing programs
Listed as “Discontinued” on FDA website





Severe allergic reactions to vaccine component or following 
previous dose
Moderate to severe acute illness
Age younger than 6 weeks




Swelling, redness, or pain in 5%-30% of recipients
Systemic reactions infrequent
Serious adverse reactions rare
